{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:17:13Z","timestamp":1794035833128,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03176-w","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T04:54:20Z","timestamp":1743656060000},"page":"2513-2525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3220-801X","authenticated-orcid":false,"given":"Christopher","family":"L\u00fcbker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0613-3571","authenticated-orcid":false,"given":"Jigish","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6640-1945","authenticated-orcid":false,"given":"Ruben","family":"Duque do Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2695-0165","authenticated-orcid":false,"given":"Scott S.","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1450-8214","authenticated-orcid":false,"given":"Emil","family":"N\u00f8rtoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-9876","authenticated-orcid":false,"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2006-4581","authenticated-orcid":false,"given":"Geraint","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Magelund","family":"Tarp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8175-2121","authenticated-orcid":false,"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"3176_CR1","unstructured":"World Health Organisation. Obesity and overweight 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 10 June 2024."},{"key":"3176_CR2","unstructured":"World Obesity Federation. World Obesity Atlas 2024. https:\/\/data.worldobesity.org\/publications\/WOF-Obesity-Atlas-v7.pdf. Accessed 26 Nov 2024."},{"issue":"10469","key":"3176_CR3","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/S0140-6736(24)01548-4","volume":"404","author":"M Ng","year":"2024","unstructured":"Ng M, Dai X, Cogen RM, et al. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990\u20132021, and forecasts up to 2050. Lancet. 2024;404(10469):2278\u201398.","journal-title":"Lancet"},{"issue":"21","key":"3176_CR4","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984\u20131010.","journal-title":"Circulation"},{"issue":"1","key":"3176_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"A Afshin","year":"2017","unstructured":"Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25\u00a0years. N Engl J Med. 2017;377(1):13\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"3176_CR6","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/ijms25031882","volume":"25","author":"P Chandrasekaran","year":"2024","unstructured":"Chandrasekaran P, Weiskirchen R. The role of obesity in type\u00a02 diabetes mellitus: an overview. Int J Mol Sci. 2024;25(3):1882.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3176_CR7","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.kint.2016.12.013","volume":"91","author":"C Garofalo","year":"2017","unstructured":"Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 2017;91(5):1224\u201335.","journal-title":"Kidney Int"},{"issue":"2","key":"3176_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/ijn.IJN_61_17","volume":"27","author":"CP Kovesdy","year":"2017","unstructured":"Kovesdy CP, Furth S, Zoccali C. Obesity and kidney disease: hidden consequences of the epidemic. Indian J Nephrol. 2017;27(2):85\u201392.","journal-title":"Indian J Nephrol"},{"issue":"2","key":"3176_CR9","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1210\/clinem\/dgab633","volume":"107","author":"C Ye","year":"2022","unstructured":"Ye C, Kong L, Zhao Z, et al. Causal associations of obesity with chronic kidney disease and arterial stiffness: a Mendelian randomization study. J Clin Endocrinol Metab. 2022;107(2):e825\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3176_CR10","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S2214-109X(24)00050-0","volume":"12","author":"M Jadoul","year":"2024","unstructured":"Jadoul M, Aoun M, Masimango IM. The major global burden of chronic kidney disease. Lancet Glob Health. 2024;12(3):e342\u20133.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"3176_CR11","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello AK, Okpechi IG, Levin A, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12(3):e382\u201395.","journal-title":"Lancet Glob Health"},{"issue":"16","key":"3176_CR12","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840\u201378.","journal-title":"Circulation"},{"issue":"20","key":"3176_CR13","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606\u201335.","journal-title":"Circulation"},{"issue":"9","key":"3176_CR14","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","volume":"30","author":"L Busetto","year":"2024","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. 2024;30(9):2395\u20139.","journal-title":"Nat Med"},{"issue":"7","key":"3176_CR15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type\u00a02 diabetes. Diabetes Care. 2011;34(7):1481\u20136.","journal-title":"Diabetes Care"},{"issue":"suppl_L","key":"3176_CR16","doi-asserted-by":"publisher","first-page":"L21","DOI":"10.1093\/eurheartj\/sui082","volume":"7","author":"LF Van Gaal","year":"2005","unstructured":"Van Gaal LF, Mertens IL, Ballaux D. What is the relationship between risk factor reduction and degree of weight loss? Eur Heart J Suppl. 2005;7(suppl_L):L21\u20136.","journal-title":"Eur Heart J Suppl"},{"issue":"17","key":"3176_CR17","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/CIRCULATIONAHA.121.056742","volume":"144","author":"IJ Neeland","year":"2021","unstructured":"Neeland IJ, McGuire DK, Sattar N. Cardiovascular outcomes trials for weight loss interventions: another tool for cardiovascular prevention? Circulation. 2021;144(17):1359\u201361.","journal-title":"Circulation"},{"key":"3176_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102782","volume":"75","author":"N Alfaris","year":"2024","unstructured":"Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type\u00a02 diabetes and obesity: a narrative review. ClinicalMedicine. 2024;75:102782.","journal-title":"ClinicalMedicine"},{"issue":"1","key":"3176_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"3176_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463\u201374.","journal-title":"Nat Rev Cardiol"},{"issue":"24","key":"3176_CR21","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"key":"3176_CR22","unstructured":"Novo Nordisk. WEGOVY (semaglutide) Prescribing Information 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215256s011lbl.pdf. Accessed 11 June 2024."},{"issue":"36","key":"3176_CR23","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415\u2013537.","journal-title":"Eur Heart J"},{"issue":"1","key":"3176_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12933-020-01034-3","volume":"19","author":"L Ludwig","year":"2020","unstructured":"Ludwig L, Darmon P, Guerci B. Computing and interpreting the number needed to treat for cardiovascular outcomes trials. Cardiovasc Diabetol. 2020;19(1):65.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3176_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12916-017-0875-8","volume":"15","author":"D Mendes","year":"2017","unstructured":"Mendes D, Alves C, Batel-Marques F. Number needed to treat (NNT) in clinical literature: an appraisal. BMC Med. 2017;15(1):112.","journal-title":"BMC Med"},{"issue":"26","key":"3176_CR26","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","volume":"318","author":"A Laupacis","year":"1988","unstructured":"Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728\u201333.","journal-title":"N Engl J Med"},{"issue":"6977","key":"3176_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","volume":"310","author":"RJ Cook","year":"1995","unstructured":"Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452\u20134.","journal-title":"BMJ"},{"issue":"2","key":"3176_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/sim.5922","volume":"33","author":"NA Gouskova","year":"2014","unstructured":"Gouskova NA, Kundu S, Imrey PB, Fine JP. Number needed to treat for time-to-event data with competing risks. Stat Med. 2014;33(2):181\u201392.","journal-title":"Stat Med"},{"issue":"6","key":"3176_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1503\/cmaj.080484","volume":"179","author":"FA McAlister","year":"2008","unstructured":"McAlister FA. The \u201cnumber needed to treat\u201d turns 20\u2013and continues to be used and misused. CMAJ. 2008;179(6):549\u201353.","journal-title":"CMAJ"},{"issue":"8","key":"3176_CR30","doi-asserted-by":"publisher","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","volume":"134","author":"DG Altman","year":"2001","unstructured":"Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663\u201394.","journal-title":"Ann Intern Med"},{"key":"3176_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c869","volume":"340","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.","journal-title":"BMJ"},{"key":"3176_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","volume":"229","author":"DH Ryan","year":"2020","unstructured":"Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61\u20139.","journal-title":"Am Heart J"},{"issue":"1","key":"3176_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/oby.23621","volume":"31","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Brown-Frandsen K, Colhoun HM, et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring). 2023;31(1):111\u201322.","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"3176_CR34","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058\u201366.","journal-title":"Nat Med"},{"issue":"8","key":"3176_CR35","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2337\/dc24-0764","volume":"47","author":"I Lingvay","year":"2024","unstructured":"Lingvay I, Deanfield J, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT. Diabetes Care. 2024;47(8):1360\u20139.","journal-title":"Diabetes Care"},{"issue":"7","key":"3176_CR36","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","volume":"30","author":"DH Ryan","year":"2024","unstructured":"Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049\u201357.","journal-title":"Nat Med"},{"issue":"17","key":"3176_CR37","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jacc.2024.08.007","volume":"84","author":"BM Scirica","year":"2024","unstructured":"Scirica BM, Lincoff AM, Lingvay I, et al. The effect of semaglutide on mortality and COVID-19-related deaths: an analysis from the SELECT trial. J Am Coll Cardiol. 2024;84(17):1632\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"3176_CR38","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.jacc.2024.08.022","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Colhoun HM, Dicker D, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT): outcomes by sex. J Am Coll Cardiol. 2024;84(17):1678\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"7223","key":"3176_CR39","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","volume":"319","author":"DG Altman","year":"1999","unstructured":"Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492\u20135.","journal-title":"BMJ"},{"issue":"16","key":"3176_CR40","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.3390\/jcm13164674","volume":"13","author":"R Le","year":"2024","unstructured":"Le R, Nguyen MT, Allahwala MA, et al. Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs. J Clin Med. 2024;13(16):4674.","journal-title":"J Clin Med"},{"issue":"9","key":"3176_CR41","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/dom.14066","volume":"22","author":"MJ Davies","year":"2020","unstructured":"Davies MJ, Kloecker DE, Webb DR, Khunti K, Zaccardi F. Number needed to treat in cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists: aA systematic review with temporal analysis. Diabetes Obes Metab. 2020;22(9):1670\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"3176_CR42","unstructured":"National Institute for Health and Care Excellence. Assessing cost effectiveness 2012. https:\/\/www.nice.org.uk\/process\/pmg6\/chapter\/assessing-cost-effectiveness. Accessed 26 Sep 2024."},{"issue":"1","key":"3176_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/hec.797","volume":"13","author":"IS Kristiansen","year":"2004","unstructured":"Kristiansen IS, Gyrd-Hansen D. Cost-effectiveness analysis based on the number-needed-to-treat: common sense or non-sense? Health Econ. 2004;13(1):9\u201319.","journal-title":"Health Econ"},{"key":"3176_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100682","volume":"18","author":"S Kumar","year":"2024","unstructured":"Kumar S, Blaha MJ. GLP-1 RA for cardiometabolic risk reduction in obesity: how do we best describe benefit and value? Am J Prev Cardiol. 2024;18:100682.","journal-title":"Am J Prev Cardiol"},{"issue":"5","key":"3176_CR45","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1192\/bjp.bp.115.163261","volume":"208","author":"SP Roose","year":"2016","unstructured":"Roose SP, Rutherford BR, Wall MM, Thase ME. Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered. Br J Psychiatry. 2016;208(5):416\u201320.","journal-title":"Br J Psychiatry"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03176-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03176-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03176-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:02:46Z","timestamp":1744876966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03176-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3176"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03176-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christopher L\u00fcbker is an employee and shareholder of Novo Nordisk A\/S. Jigish Bhavsar is an employee of Novo Nordisk Inc. and shareholder of Novo Nordisk A\/S. Ruben Duque do Vale is an employee and shareholder of Novo Nordisk A\/S. Scott S. Emerson declares having received consulting honoraria from Amylyx, AstraZeneca, Avillion, Ayala, Bayer, BeiGene, Boehringer Ingelheim, 89 Bio, BioAge, BioAtla, Bristol Meyer Squibb, BridgeBio, Daiichi Sankyo, Denovo, Fore Therapeutics, GlaxoSmithKline, Inovio, Insmed, Ipsen, Karuna, Lilly, Lundbeck, Mirati, Moderna, Novartis, Novavax, Novo Nordisk, NSABP, Pfizer, Principia, Reata, Rebiotx, Roche, Sanofi, SOLVD, Sutro Biopharma, and TG Therapeutics. Emil N\u00f8rtoft is an employee of Novo Nordisk A\/S. Jorge Plutzky declares having received consulting honoraria from Altimmune, Amgen, Esperion Therapeutics, Inc., Merck, MJH Life Sciences, Novartis, and Novo Nordisk and has received a grant, paid to his institution, from Boehringer Ingelheim. Geraint Roberts is an employee of HEOR Ltd., who received fees from Novo Nordisk A\/S in relation to this study. Jens Magelund Tarp is an employee of Novo Nordisk A\/S. A. Michael Lincoff declares having received research grants paid to his institution from AbbVie Inc., AstraZeneca, CSL Behring, Eli Lilly and Company, Esperion Therapeutics, Inc., and Novartis and has served as a consultant for Akebia Therapeutics Inc, Alnylam Pharmaceuticals Inc., Ardelyx, Eli Lilly and Company, FibroGen, GlaxoSmithKline, Intarcia, Medtronic Vascular, Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, Provention Bio, Entity, and ReCor Medical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The SELECT trial protocol was reviewed by national and institutional regulatory and ethical authorities in each participating country, and the trial was conducted at 804 sites across 41 countries. All patients provided written informed consent before beginning any trial-related activity. The SELECT study was conducted in line with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The present analysis did not require informed consent or institutional\/ethical review board approval since the analysis does not report any new studies with human participants or animals performed by any of the authors and was based on the previously conducted clinical trial. Any clinical data were anonymized for the purpose of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}